# CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct04718883/  
OnCo record `nct04718883` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells in mantle cell lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.

## Summary

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT04718883 by Shanghai Ming Ju Biotechnology Co., Ltd., with 59 participants enrolled, started 2021-01-13 and due to reach its primary completion in 2023-10-25. Interventions recorded: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04718883
- Phase: 2
- Setting: A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
- Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.
- Enrolled: 59

## Sources

- ClinicalTrials.gov NCT04718883: https://clinicaltrials.gov/study/NCT04718883

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- companies: [JW Therapeutics](https://onco.cc/companies/jw-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04718883.json